Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 3,074 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $76,850.00. Following the completion of the transaction, the insider now owns 127,634 shares in the company, valued at approximately $3,190,850. This trade represents a 2.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Peter Heerma also recently made the following trade(s):

• On Wednesday, January 22nd, Peter Heerma sold 1,584 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total transaction of $30,000.96.

Travere Therapeutics Trading Down 3.4 %

Travere Therapeutics stock traded down $0.81 on Friday, hitting $22.91. 1,466,790 shares of the stock traded hands, compared to its average volume of 1,303,585. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The business's fifty day simple moving average is $19.22 and its 200 day simple moving average is $16.14. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $25.29.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TVTX. RA Capital Management L.P. bought a new position in shares of Travere Therapeutics during the fourth quarter valued at $20,033,000. Jennison Associates LLC bought a new stake in Travere Therapeutics in the 4th quarter worth about $14,222,000. Renaissance Technologies LLC boosted its position in Travere Therapeutics by 28.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company's stock worth $41,974,000 after purchasing an additional 534,500 shares during the last quarter. Invesco Ltd. boosted its position in Travere Therapeutics by 135.2% in the fourth quarter. Invesco Ltd. now owns 858,942 shares of the company's stock worth $14,963,000 after purchasing an additional 493,736 shares during the last quarter. Finally, abrdn plc purchased a new position in Travere Therapeutics in the fourth quarter worth about $6,829,000.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Barclays upped their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. Canaccord Genuity Group increased their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday. Piper Sandler increased their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, November 14th. Evercore ISI increased their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday. Finally, Wells Fargo & Company raised Travere Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $9.00 to $27.00 in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $27.77.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.